Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection for the treatment of Macular Edema following Retinal Vein Occlusion (RVO), which includes macular oedema following branch retinal vein occlusion (BRVO) in addition to the previously-approved indication of macular oedema following central retinal vein occlusion (CRVO). The recommended dosage of Eylea in patients with macular oedema following RVO is 2 mg every month (4 weeks).

"RVO is a significant cause of vision impairment in the U.S., and this expanded indication across all forms of RVO will provide an important new treatment option for retina specialists and their patients," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories. "Regeneron remains committed to studying Eylea for the treatment of multiple VEGF-driven retinal diseases."

For more details, go to: http://investor.regeneron.com/releases.cfm